Loading...
•
Jun 30, 2021
CorMedix Q2 2021 Earnings Report
Reported a net loss due to increased personnel expenses and a lower tax benefit from the NJ NOL program, partially offset by raw materials purchased during 2Q of 2020.
Key Takeaways
CorMedix reported a net loss of $4.6 million, or $0.12 per share, for the second quarter of 2021, compared to a net loss of $3.8 million, or $0.14 per share, for the second quarter of 2020. Operating expenses decreased by approximately 34% to $5.9 million, compared with $8.9 million in the second quarter of 2020. Total cash on hand and short-term investments as of June 30, 2021, was $78.3 million.
Net loss of $4.6 million, or $0.12 per share, compared to a net loss of $3.8 million, or $0.14 per share, in Q2 2020.
Operating expenses decreased approximately 34% to $5.9 million.
R&D expense decreased approximately 56% to $2.5 million.
Total cash on hand and short-term investments as of June 30, 2021 was $78.3 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...